Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 601 to 606 of 606

Publication Record

Connections

Internephron heterogeneity in susceptibility to glomerular sclerosis and responsiveness to therapeutic measures.
Yoshida Y, Ikoma M, Kawamura T, Fogo A, Ichikawa I
(1991) Contrib Nephrol 95: 107-11
MeSH Terms: Angiotensin-Converting Enzyme Inhibitors, Animals, Glomerulosclerosis, Focal Segmental, Humans, Hypertrophy, Kidney Glomerulus, Nephrons
Added January 20, 2012
1 Communities
1 Members
0 Resources
7 MeSH Terms
Angiogenic action of angiotensin II is important for the glomerular growth of maturing kidneys.
Fogo A, Ichikawa I
(1991) Kidney Int Suppl 32: S37-8
MeSH Terms: Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Animals, Kidney Glomerulus, Neovascularization, Pathologic, Rats, Rats, Inbred Strains
Added January 20, 2012
1 Communities
1 Members
0 Resources
7 MeSH Terms
Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects.
Guengerich FP, Kim DH, Iwasaki M
(1991) Chem Res Toxicol 4: 168-79
MeSH Terms: Acrylonitrile, Animals, Antibodies, Benzene, Carcinogens, Cytochrome P-450 CYP2E1, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Enzyme System, Ditiocarb, Humans, Hydrocarbons, Chlorinated, Kinetics, Microsomes, Liver, Molecular Weight, Oxidation-Reduction, Oxidoreductases, N-Demethylating, Rats, Styrene, Styrenes, Urethane, Vinyl Compounds
Show Abstract · Added March 5, 2014
The role of human cytochrome P-450 IIE1 (P-450 IIE1) in the oxidation of a number of suspect carcinogens was examined by using a variety of approaches, including (1) selective inhibition of catalytic activity in human liver microsomes by diethyldithiocarbamate, which was found to be a selective mechanism-based inactivator of P-450 IIE1, (2) correlation of rates of different catalytic activities with each other and with chlorzoxazone 6-hydroxylation, an indicator of P-450 IIE1, in human liver microsomes, (3) demonstration of catalytic activity in reconstituted systems containing purified human P-450 IIE1, and (4) immunoinhibition of catalytic activity in human liver microsomes with rabbit anti-human P-450 IIE1. The results collectively indicate that P-450 IIE1 is a major catalyst of the oxidation of benzene, styrene, CCl4, CHCl3, CH2Cl2, CH3Cl, CH3CCl3, 1,2-dichloropropane, ethylene dichloride, ethylene dibromide, vinyl chloride, vinyl bromide, acrylonitrile, vinyl carbamate, ethyl carbamate, and trichloroethylene. Levels of P-450 IIE1 can vary considerably among individual humans--the availability of chlorzoxazone as a noninvasive probe of human P-450 IIE1 and of disulfiram (oxidized diethyldithiocarbamate) as an inhibitor may facilitate discernment of the in vivo significance of human P-450 IIE1 as a factor in the bioactivation and detoxication of these cancer suspects. Further, many investigations with diethyldithiocarbamate, disulfiram, and ethanol in humans and experimental animals may be interpreted in light of mechanisms involving P-450 IIE1.
0 Communities
1 Members
0 Resources
21 MeSH Terms
Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure.
Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A
(1992) Kidney Int 42: 46-55
MeSH Terms: Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Animals, Blood Pressure, Blood Vessels, Cardiovascular System, Imidazoles, Kidney Failure, Chronic, Kidney Glomerulus, Male, Rats, Rats, Inbred Strains, Tetrazoles
Show Abstract · Added January 20, 2012
Previous studies in experimental models of progressive renal failure have shown that the capacity of antihypertensive drugs to protect glomeruli from sclerosis is often unpredictable from their effect on systemic blood pressure. The present study was undertaken to ascertain whether this systemic blood pressure-independent structure-preserving effect of antihypertensives, particularly angiotensin II converting enzyme inhibitors (ACEI), is confined to the glomerulus or not, as well as whether this effect is mediated via angiotensin II (Ang II). The following experimental drug regimens were used in the rat model of subtotal nephrectomy (sNPX): so-called triple therapy [TRX; a combination of reserpine 5 mg/liter drinking water (DW), hydralazine 80 mg/liter DW and hydrochlorothiazide 25 mg/liter DW], or ACEI (either captopril, CPL, 600 mg/liter DW, enalapril, ENL, 400 mg/liter DW or lisinopril, LSL, 200 mg/liter DW), or a novel Ang II receptor antagonist (Ang IIR, L-158,809, 20 mg/liter DW). These dosages were identified in pilot studies to be the minimum required to control systemic blood pressure in the early phase up to 12 weeks. In addition, a separate group was treated with a higher dose of L-158,809 (80 mg/liter DW) with equipotent systemic pressor effect. Treatment was initiated eight weeks after subtotal nephrectomy following renal biopsy, and animals were sacrificed at 16 weeks. In ACEI treated rats, carotid arterial wall thickening (WT), defined as ratio of media thickening to radius of outer vessel wall, was similar to normal age-matched control (0.073 in all ACEI treated rats, vs. 0.074 in normal control) and significantly less than with TRX (ratio 0.118) or untreated sNPX (0.130). Even more remarkably, coronary arteriole WT in ACEI-treated rats averaged 0.139, a value less than one half and one third of TRX (0.298) and untreated sNPX control (0.388), respectively. Similar results were obtained for mesenteric artery WT. These findings were closely paralleled by changes of glomerular sclerosis. In untreated sNPX control rats, glomerular sclerosis increased from biopsy to autopsy specimens by an average of 458%. Although TRX dampened the degree of increase in sclerosis to on average 212%, this protective effect was far less than that achieved by ACEI. In the latter, sclerosis increased on average only 65% from biopsy to autopsy. Although all ACEIs were more effective than TRX, captopril and lisinopril groups showed greatest benefit at these doses. Ang IIR also protected renal and extrarenal structures with 34% increase of sclerosis index in low dose and WT 0.088, 0.117 and 0.112, respectively in carotid, mesenteric and coronary arteries.(ABSTRACT TRUNCATED AT 400 WORDS)
1 Communities
1 Members
0 Resources
13 MeSH Terms
Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.
Piper JM, Ray WA, Rosa FW
(1992) Obstet Gynecol 80: 429-32
MeSH Terms: Abnormalities, Drug-Induced, Adolescent, Adult, Angiotensin-Converting Enzyme Inhibitors, Anuria, Cohort Studies, Encephalocele, Female, Humans, Hypertension, Infant, Newborn, Microcephaly, Pregnancy, Pregnancy Complications, Cardiovascular, Pregnancy Outcome, Tennessee
Show Abstract · Added March 5, 2014
OBJECTIVE - Case reports of suspected adverse pregnancy outcomes associated with prenatal exposure to angiotensin-converting enzyme inhibitors, particularly oligohydramnios, prolonged neonatal anuria, and defects of ossification of the skull dome, prompted us to examine pregnancy outcome in a large cohort of pregnant women for whom complete drug exposure information was known.
METHODS - We studied the prescribed drug exposure histories and pregnancy outcomes of all women aged 15-44 years enrolled in Tennessee Medicaid who delivered a live-born or stillborn infant between January 1, 1983 and December 31, 1988.
RESULTS - Of the 106,813 women enrolled in Tennessee Medicaid who delivered either a live-born or stillborn infant during the study period, 19 were exposed to an angiotensin-converting enzyme inhibitor during pregnancy. All 19 women delivered live infants. Among the 19 newborns, one preterm infant had prolonged anuria necessitating dialysis and a second preterm infant had microcephaly and a large occipital encephalocele.
CONCLUSIONS - These outcomes represent a systematic follow-up of all angiotensin-converting enzyme inhibitor-exposed pregnancies. Despite the small number of exposures, there were two outcomes previously linked to prenatal use of these drugs, suggesting that the absolute risk may be high. In light of these findings and the case reports of others, it is prudent to avoid the use of angiotensin-converting enzyme inhibitors in pregnancy.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Modification of cytochrome P450 1A2 enzymes by the mechanism-based inactivator 2-ethynylnaphthalene and the photoaffinity label 4-azidobiphenyl.
Yun CH, Hammons GJ, Jones G, Martin MV, Hopkins NE, Alworth WL, Guengerich FP
(1992) Biochemistry 31: 10556-63
MeSH Terms: Affinity Labels, Amino Acid Sequence, Animals, Azides, Biphenyl Compounds, Chromatography, High Pressure Liquid, Cytochrome P-450 CYP1A2, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Enzyme System, Humans, Microsomes, Liver, Molecular Sequence Data, Naphthalenes, Oxidoreductases, Peptide Mapping, Photochemistry, Rabbits, Rats, Sequence Alignment
Show Abstract · Added March 5, 2014
2-Ethynylnaphthalene (2EN) had previously been demonstrated to be a mechanism-based inactivator of rat cytochrome P450 (P450) 1A2 [Hammons, G.J., Alworth, W.L., Hopkins, N.E., Guengerich, F. P., & Kadlubar, F. F. (1989) Chem. Res. Toxicol. 2, 367-374]. In this work 2EN was also demonstrated to be a useful inactivator of rabbit P450 1A2 (k(inactivation) 0.094 min-1, K(i) 11 microM) but it did not inactivate human P450 1A2, although the sequences of the three proteins are approximately 80% identical. Rat and rabbit P450 1A2 were modified by incubation with NADPH-P450 reductase, NADPH, and [3H]2EN to levels of 0.35 and 0.47 nmol of adduct (nmol of P450)-1, respectively. In each case only a single tryptic peptide was labeled; recovery of labeled peptides was low under the acidic HPLC conditions. The rabbit P450 1A2 peptide FQELMAAVGR (positions 175-184) and the rat P450 1A2 peptide L(S)QQYGDVLQIR (positions 67-78) were identified. 4-Azidobiphenyl (4-N3BP) was developed as a photoaffinity label for P-450 1A2 proteins because of its similarity to 4-aminobiphenyl, a known substrate for the enzymes. 4-N3BP was shown to be photolyzed with 350-nm light and radioactive label could be incorporated into rat P450 1A2. Labeling of the protein was found to be saturable with increasing concentrations of 4-N3BP and up to 0.59 nmol of label could be incorporated (nmol P450 1A2)-1. The substrate 4-aminobiphenyl and the competitive inhibitor 7,8-benzoflavone blocked photolabeling of P450 1A2 with 4-N3BP, and 4-N3BP inhibited N-hydroxylation of 4-aminobiphenyl by P450 1A2 in the usual enzyme assay.(ABSTRACT TRUNCATED AT 250 WORDS)
0 Communities
1 Members
0 Resources
19 MeSH Terms